Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
AssigneeAmgen Inc.
InventorsJeffrey Scott Wiezorek, Jonathan David Graves, Jennifer Joy Kordich
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treatment of exocrine pancreatic cancer in a human patient comprising administering a therapeutically effective amount of a DR5 agonist and gemcitabine. Methods and compositions for treating a patient by identifying the alleleic variant of FcγRIIIA.
Claims19
A method for inhibiting the growth of adenocarcinoma of the pancreas in a human patient comprising administering to said patient a therapeutically effective amount of a DR5 agonist and gemcitabine.
A method for inhibiting the growth of adenocarcinoma of the pancreas in a human patient comprising:
- (a) identifying a human patient with an adenocarcinoma of the pancreas wherein said patient is homozygous or heterozygous for the valine158 polymorphism in FcγRIIIA;
- (b) administering to said patient a therapeutically effective amount of a DR5 agonist and gemcitabine, wherein said DR5 agonist is an IgG1 antibody or IgG1 Fc-peptide fusion.
A method for inhibiting the growth of adenocarcinoma of the pancreas in a human patient comprising:
- (a) identifying a human patient with an adenocarcinoma of the pancreas wherein said patient is homozygous or heterozygous for the phenylalanine158 polymorphism in FcγRIIIA;
- (b) administering to said patient a therapeutically effective amount of a DR5 agonist and gemcitabine, wherein said DR5 agonist is an IgG1 antibody or IgG1 Fc-peptide fusion.
A method of selecting a human patient with adenocarinoma of the pancreas for treatment with a therapeutically effective amount of a DR5 agonist and gemcitabine, comprising:
- (a) identifying the genotype for FcγRIIIA of said patient for the F158 or V158 allele;
- (b) selecting a patient that is heterozygous or homozygous for the V158 allele of FcγRIIIA for said treatment.
Dependencies are inferred from the claim text.